Expression and functional analysis of rat P23, a gut hormone-inducible isoform of trypsin, reveals its resistance to proteinaceous trypsin inhibitors  by Fukuoka, Shin-Ichi & Nyaruhucha, Cornelio M
Expression and functional analysis of rat P23, a gut hormone-inducible
isoform of trypsin, reveals its resistance to proteinaceous trypsin inhibitors
Shin-Ichi Fukuoka*, Cornelio M. Nyaruhucha
Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Uji, Kyoto 611, Japan
Received 13 November 2001; received in revised form 16 May 2002; accepted 30 May 2002
Abstract
Rat P23 is an isoform of trypsin (ogens) synthesized by rat acinar cells. Expression of P23 is stimulated strongly by caerulein, an analogue
of cholecystokinin (CCK). However, the physiological relevance of rat P23 in healthy and pathological conditions such as caerulein-induced
pancreatitis is largely unknown. Using recombinant P23 trypsinogen and reconstitution analysis of zymogen autoactivation, unique inhibitor-
resistance characteristics of P23 were elucidated. P23 cDNA was expressed in Escherichia coli periplasm, yielding recombinant P23
trypsinogen. Autoactivation of zymogen granule contents from caerulein-induced rat pancreas was also studied. Activation kinetics of P23 by
enterokinase was similar to those of rat anionic trypsinogen, which is a major isoform of trypsinogen. Interestingly, rat pancreatic secretory
trypsin inhibitor (PSTI), which protects against deleterious activation of trypsinogens in zymogen granules, failed to inhibit P23 trypsin even
with four-fold molar excess, at which concentration it effectively inhibited rat anionic trypsin to almost 100%. P23 trypsin also showed
marked resistance to proteinaceous trypsin inhibitors such as soybean trypsin inhibitor and aprotinin. P23 trypsin activated by enterokinase
dramatically accelerated the cascade of autoactivation of anionic trypsinogen even in the presence of PSTI. Taken together with a previous
observation that P23 is specifically upregulated 14-fold by 24-h caerulein infusion, these results suggest that elevated levels of P23 should be
taken into consideration in the mechanism of trypsinogens within the pancreas in pathological conditions.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
P23 was found originally in rat exocrine pancreas by
two-dimensional isoelectric focusing and SDS-PAGE to be
an unidentified protein with Mr=23,000 and an isoelectric
point (pI) of 6.2 [1]. P23 is expressed only in trace amounts
(<0.4% of total secretory proteins) in the unstimulated
pancreas while caerulein, an analog of the physiological
pancreatic secretagogue cholecystokinin (CCK), causes an
acute 14-fold induction of P23 protein synthesis, so that it
comprises up to 2% of total secretory proteins [1]. By this
criterion, P23 is the most strongly regulated protein of the
rat exocrine pancreas. Molecular cloning using a specific
antibody against P23 revealed that rat P23 cDNA encodes a
novel isoform of trypsinogen, whose similarities in amino
acid sequence to two anionic (trypsinogen 1 and 2) and one
basic (trypsinogen 3) isoform previously identified in the rat
pancreas are 67%, 68% and 72%, respectively [2]. P23
contains all the major structural features of other trypsins [2].
Thus far, the physiological role and hormonal regulation
of P23 are relatively unknown. Here, we describe the
experimental expression and functional analysis of rat P23
and its unique inhibitor resistance.
2. Materials and methods
2.1. Materials
Rat anionic trypsinogen and pancreatic secretory trypsin
inhibitor (PSTI) were purified from pure rat pancreatic juice
collected from rats under anesthesia as described in Ref. [3].
Purified bovine trypsin (Type III) was purchased from Sigma.
Enterokinase was purchased from NEB. A synthetic trypsin
substrate, benzoyl-arginine-p-nitroanilide (BApNA) and an
expression inducer, isopropyl-beta-D()-thiogalactopyrano-
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side (IPTG) were purchased from Wako Pure Chemicals.
Protein concentration was determined using Bio-Rad protein
assay reagent. Recombinant enterokinase and reagents for
DNAmanipulation were purchased fromNEB. FOY-305was
provided from Ono Pharmaceutical Co., Ltd.
2.2. Construction of a P23 expression vector in Escherichia
coli periplasm
Two oligonucleotide primers were used for polymerase
chain reaction (PCR). The sense primer 5V-GATGACAAG-
CTTGTTGGAGGCTACA-3V, corresponding to amino acid
residues 21–29 of P23, was designed to contain HindIII
restriction sites. M13–20 primer was utilized as an antisense
primer. PCR was performed using P23 cDNA cloned into
pBluescript [2] as a template, with Taq/Pfu polymerases.
Samples were amplified for 25 cycles under the following
conditions: denaturation for 1 min at 94 jC, annealing for 1
min at 55 jC and extension for 1 min at 72 jC. A DNA
fragment of approximately 750 bp was treated with HindIII,
isolated by electrophoresis on a 0.7% agarose gel, and
recovered with a Gene Clean kit (Bio 101). The fragment
was subcloned into the prokaryotic expression vector pFlag-
1 (IBI) at its HindIII site as described previously [4]. The
DNA sequence was determined to confirm insertion and
integrity of the P23 sequence. Restriction enzyme analysis
was also performed to determine the orientation of the
inserts. Both constructs with normal and reversed (as a
control) orientations relative to the promoter in pFlag-1
were selected for the following expression study.
2.3. Expression of P23 protein in E. coli periplasm
E. coli JM109 strains were transformed by pFlag carry-
ing P23 or reversed P23 inserts using a standard calcium
chloride method. Transformants were selected on plates
containing ampicillin (50 Ag/ml). Plasmid DNA was puri-
fied from these transformants and restriction patterns were
checked with several restriction enzymes for DNA integrity.
Transformants were preincubated at 37 jC with vigorous
shaking in LB media with ampicillin to achieve log phase
growth, at which point IPTG was added (0.05 mM).
Periplasmic expression and purification were performed as
described in Ref. [4]. Briefly, cells were harvested by
centrifugation after 3 h incubation with IPTG in the pres-
ence of 5 mM reduced glutathione. Cells were washed with
a Tris–HCl buffer, pH 7.5 containing 1 mM EDTA, and
then treated with lysozyme (0.1 mg/ml) in the same buffer at
4 jC for 30 min. Periplasmic proteins were recovered in the
supernatant after centrifugation at 10,000g for 20 min.
Expressed P23 was purified further by two cycles of
sedimentation with ammonium sulfate and by HPLC with
a TSK3000 gel filtration column. Elution was monitored by
measuring absorbance at 280 nm and performing SDS-
PAGE. Fractions with a molecular weight of 23 kDa and
trypsin activity were pooled and stored at 20 jC until use.
A control transformant with a Flag-1 vector carrying a
reversed P23 insert was treated in the same manner and
the periplasmic fraction was mock-purified with ammonium
sulfate and by HPLC and then used as a control solution for
enzyme assay.
2.4. Enzyme assay
The recombinant P23, reversed P23 fraction or purified
anionic trypsinogen (100 Ag/ml) was activated with enter-
okinase (1 Ag/ml) at 37 jC for 40 min, and then BApNA (2
mM) was added. The mixtures were incubated at 37 jC. At
given time points, a portion of each reaction was collected
and the reaction stopped by addition of acetic acid (20%). p-
Nitroanilines liberated by trypsin activity were measured
with a spectrophotometer at 410 nm. Dependency of the
reactions on enterokinase activation was studied by per-
forming the same reaction in the absence of enterokinase
and comparing the results.
2.5. Effects of trypsin inhibitors on the recombinant P23 and
native anionic trypsins
Recombinant P23 or purified anionic trypsinogen was
activated with enterokinase as described above, and then
various proteinaceous or synthetic trypsin inhibitors were
added at various inhibitor/enzyme ratios. The reaction
mixtures were incubated at 22 jC for 15 min to allow
inhibitor/enzyme interaction, and then BApNA was added.
Reactions were carried out and stopped as described earlier.
Inhibitor-resistant trypsin activity was expressed as a per-
centage of the activity in control reactions without inhib-
itors.
2.6. In vitro studies of acceleration of autoactivation by rat
P23 trypsin
Highly purified rat anionic trypsinogen (90 Ag/ml) was
incubated with recombinant P23 trypsinogen (10 Ag/ml)
for various periods of time in the presence or absence of
enterokinase (0.1 Ag/ml) and/or purified rat PSTI (2 Ag/
ml) at 37 jC. Experiments conducted without addition of
P23 trypsinogen were controlled by addition of an
equivalent amount of anionic trypsinogen (10 Ag/ml), in
order to maintain a total of 100 Ag/ml trypsinogen in the
reaction mixtures. The amount of P23 trypsinogen to be
added was estimated to be similar to those found in rat
pancreatic secretions after 24-h stimulation by caerulein
(about one-tenth of total anionic trypsinogens) [1]. The
amount of PSTI to be added was made to be similar to
physiological conditions, which effectively inhibits about
5% of total trypsin activity in pancreatic secretions [5].
At given time points, portions of the samples were
collected and assayed with BApNA for activated trypsin
activity. Trypsin-like activity of enterokinase toward
BApNA was negligible.
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3. Results
3.1. Expression of P23 trypsinogen as a secretory protein in
E. coli periplasm
E. coli transformed with pFlag-1 carrying P23 cDNA
produced a protein with a molecular mass corresponding to
a trypsinogen (23 kDa) in the periplasm, representing about
10% of all periplasmic proteins upon IPTG induction (Fig.
1, lane 1 vs. 2). As a control, E. coli with pFlag-1 carrying
reverse-oriented P23 cDNA did not express any significant
protein at the corresponding molecular weight with or
without IPTG (Fig. 1, lanes 3 and 4). Western blotting
using polyclonal anti-dog trypsinogen antibody was weakly
positive, confirming that the 23-kDa band in lane 2 is a
trypsinogen-related molecule (data not shown). A large
portion ( > 90%) of the expressed P23 protein remained in
insoluble forms in the bacteria even after lysis with 1%
Triton X-100. SDS-PAGE with beta-mercaptoethanol
showed that inclusion bodies contained a protein with a
molecular mass of about 25 kDa, suggesting that the soluble
form of P23 was translocated to the periplasm and an Omp
A signal peptide (with a predicted size of 2046 Da for 21
amino acids) was released, resulting in formation of a
proenzyme (P23 trypsinogen) form in the periplasm. The
apparent low efficiency of translocation may be due to
saturation of the E. coli translation machinery with a high
level of exogenous protein expression. The expressed P23
trypsinogen in the periplasm was further purified by two
rounds of ammonium sulfate precipitation and HPLC gel
filtration, producing a homogenous sample to be used for
enzymatic assays.
3.2. Enteropeptidase-dependent activation of P23 trypsino-
gen
Expressed P23 trypsinogen showed enteropeptidase-
dependent activation, with a time-dependent profile similar
to that of purified rat anionic trypsinogen (Fig. 2). A control
preparation similarly purified from E. coli periplasm trans-
formed with the reversed P23 cDNA did not show any
significant trypsin activity either in the presence or absence
of enteropeptidase, indicating efficient separation of
recombinant P23 from endogenous E. coli proteases by
the purification (data not shown).
3.3. Inhibition of P23 trypsin with various trypsin inhibitors
The effect of various trypsin inhibitors on P23 trypsin
was compared with their effects on rat anionic trypsin and
bovine trypsin. Increasing concentrations of inhibitors were
incubated with 100 Ag/ml of each trypsin, and then the
remaining resistant trypsin activities were measured. Rat
anionic and bovine trypsins were completely inhibited by
equimolar (100 Ag/ml) soybean trypsin inhibitor (SBTI),
whereas P23 was inhibited by 20–30% with the same
concentration of SBTI (Fig. 3A). Similar results were
obtained when P23 was mixed with rat pancreatic secretory
trypsin inhibitor (rPSTI), a physiological inhibitor present
together with trypsinogens in the zymogen granules, possi-
bly to prevent premature trypsin activation. In the presence
of a four-fold molar excess of rPSTI (100 Ag/ml), control
trypsins were inhibited completely, whereas more than 95%
of the original P23 activity remained (Fig. 3B). A very
similar profile was obtained when these trypsins were
challenged by bovine pancreatic trypsin inhibitor (BPTI),
Fig. 1. Expression of recombinant P23 trypsinogen in E. coli periplasm. E.
coli transformed with pflag-1 carrying P23 cDNA (lanes 1 and 2) or
reverse-oriented p23 cDNA (lanes 3 and 4) were incubated in LB media
with (lanes 2 and 4) or without (lanes 1 and 3) IPTG. Cells were harvested
and the periplasmic fractions were subjected to 10% SDS-PAGE. Apparent
molecular weight shown by prestained molecular markers are indicated as
kDa at far left. P23 trypsinogen purified by ammonium sulfate
precipitation/HPLC gel filtration is indicated in lane 5 with an arrow head.
Fig. 2. Enterokinase-dependent activation of rat anionic and p23 tryp-
sinogens. Recombinant rat P23 trypsinogen (closed symbols) or purified rat
anionic trypsinogen (open symbols) (100 Ag/ml) were incubated in the
presence (square) or absence (circle) of enterokinase (1 Ag/ml). Samples
were taken at given incubation times, mixed with BApNA (2 mM) as a
substrate and incubated again at 37 jC for 15 min. p-Nitroanilides liberated
by trypsin cleavage were measured with a spectrophotometer (Beckman
DU-650) at 410 nm. Trypsin activity was expressed as the rate of A410
increase per minute.
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also known as aprotinin or Trasylol, a strong, widely used
trypsin inhibitor in both experimental and clinical settings
(Fig. 3C). However, P23 was sensitive to synthetic serine
protease inhibitors such as PMSF (Fig. 3D) and TLCK (Fig.
3E) at concentrations comparable to those used to inhibit rat
anionic trypsin and bovine trypsin, confirming that P23 is a
member of the serine protease family. When FOY-305, a
low molecular weight inhibitor, was used, rat P23 trypsin
Fig. 3. Inhibition profiles of rat p23 trypsin, rat anionic trypsin and bovine trypsin with various trypsin inhibitors. One hundred microgram per milliliter each of
recombinant p23 trypsin (closed circle), purified rat anionic trypsin (open circle), or bovine trypsin (open square) was activated with enterokinase (1 Ag/ml) as
described and then incubated with one of the given trypsin inhibitors at various concentrations as indicated at 22 jC for 15 min. Residual trypsin activity was
assayed using BApNA and expressed as a percentage of total activity without the inhibitor. (A) Soybean trypsin inhibitor (SBTI), (B) rat pancreatic secretory
trypsin inhibitor (rPSTI), (C) bovine pancreatic trypsin inhibitor (BPTI/aprotinin), (D) phenylmethylsulfonylfluoride (PMSF), (E) p-toluenesulfonyl-l-lysine
chloromethyl ketone (TLCK), (F) FOY-305 (n,n-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy) phenylacetate methane sulfate). Data are expressed as
the mean of three experiments, all of which varied less than 5%.
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was more resistant than rat anionic and bovine trypsins (Fig.
3F), but was almost completely inhibited at higher FOY-305
concentrations.
3.4. In vitro studies of autoactivation acceleration by rat
P23 trypsin
Based on the observation that P23 trypsin shows resis-
tance to PSTI, which is thought to protect against trypsi-
nogen autoactivation, an experiment to assess the ability of
increased levels inhibitor-resistant P23 trypsinogen to
induce autoactivation was performed in vitro.
When purified anionic trypsinogen was incubated with or
without purified recombinant P23 trypsinogen (at 9:1 molar
ratio) at 37 jC up to 16 h, trypsin autoactivation was not
detected in either sample (Fig. 5). This finding indicates that
purified trypsinogens are stable and not activated sponta-
neously under such conditions. When a small amount of
enterokinase, an artificial initiator of activation, was added,
anionic trypsinogens, with or without P23 trypsinogen, were
all activated very quickly. When similar experiments were
performed in the presence of purified PSTI, a physiological
inhibitor of trypsin autoactivation, anionic trypsinogen was
only slowly activated by enterokinase, indicating that PSTI
attenuates the initial rate of trypsin autoactivation. On the
other hand, when P23 trypsinogen was present in the
reaction mixture, trypsin activation was accelerated dramat-
ically, suggesting that P23 trypsinogen was activated by
enterokinase to P23 trypsin, a PSTI-resistant enzyme that
could promote the cascade of trypsin autoactivation free
from PSTI control. The autoactivation promoted by the
activated P23 trypsin was observed to overcome PSTI
inhibitory effects on the other trypsinogens after an initial
period of time. In conclusion, these results indicate that P23
trypsinogen is stable and does not promote trypsin autoacti-
vation by itself but requires activation by an independent
initiator (enterokinase, present in this experimental case but
absent in the exocrine pancreas).
4. Discussion
Based on observations presented here, rat P23 trypsin
(ogen) appears to be a unique isoform of trypsin, which is
resistant to proteinaceous trypsin inhibitors such as PSTI
and SBTI. A similar isoform of trypsin has been described
in human pancreatic secretions and named mesotrypsin, due
to its pI of 5.95, which is ‘meso’, or in the middle, between
other acidic and basic trypsins [6,7]. Human mesotrypsin is
a minor species of pancreatic digestive enzyme and shows
resistances to naturally occurring trypsin inhibitors similar
to those exhibited in P23. Structural and functional analyses
suggest that rat P23 trypsinogen is a functional homologue
of human mesotrypsinogen. However, the degree to which
human mesotrypsinogen is regulated by CCK or its ana-
logues should be investigated further. Structural comparison
of rat P23 and human mesotrypsinogen revealed several
unique characteristics. Upon comparison of rat P23 or
human mesotrypsin to other known trypsin isoforms, it is
found that the catalytic triad of His-63, Asp-107 and Ser-
201 (numbers are based on the rat P23 sequence), as well as
an obligatory Asp at position 194, are all conserved.
However, at amino acid 198, close to the active center of
the enzyme, an Asp residue is found in P23, rather than an
Asn, which is conserved throughout all known rat and
human trypsins (Fig. 4). This substitution may change the
Fig. 4. Comparison of amino acid sequences of various trypsin active sites. Number corresponding to amino acid residues in rat p23 trypsinogen are indicated
at the top. Residue 195 is an obligatory Asp that determines substrate specificity toward basic amino acids and is conserved in all rat and human trypsins.
Residue 200 is the active serine in the triad and is also conserved in all rat and human trypsins. Note the unique Asp-198, instead of Asn, in rat p23 and the
unique Arg-199 in human mesotrypsinogen, which may be responsible for their altered interactions with trypsin inhibitors. Ta, anionic trypsin (two different
anionic trypsins have been described in rats); Tc, cationic trypsin.
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electrical and steric environment in the active center. A
similar, in terms of site, but different, in terms of amino acid
charge, substitution has been found in human mesotrypsin,
which has an Arg instead of the conserved Gly in position
199.
Based upon an X-ray crystallographic structure of a
complex between rat trypsin and BPTI [8], the Asp!Asn
mutation at position 198 was modeled using the software
Quanta (Molecular Simulations). The Van der Waals radii of
Asp-198 in rat P23 and Arg-17 in BPTI were found to
overlap for all possible rotations (data not shown). This
suggests that the two residues cannot co-exist in the com-
plex as it is currently structured, and would disrupt the
binding between the enzyme and inhibitor. Further analysis
of the change of the microscopic molecular environment in
the active center of P23 and mesotrypsin could explain why
they are not inhibited by large proteinaceous trypsin inhib-
itors such as PSTI, BPTI and SBTI, but can be blocked
using small synthetic trypsin inhibitors such as PMSF and
TLCK.
The fact that P23, a hormone-inducible trypsin isoform,
exhibits marked inhibitor resistance implies that it may
perform several physiologically relevant functions. If levels
of rat P23 trypsin are increased by a specific stimulus such
as CCK, caerulein or by pathogenic conditions, the inhib-
itor-resistant trypsin may cause potentially deleterious
effects upon autoactivation within pancreatic tissues, espe-
cially in the setting of pancreatitis. Caerulein-induced pan-
creatitis is a widely acknowledged model as an experimental
pancreatitis [9]. Supramaximal doses of CCK, caerulein or
cholinergic agonists have been found to induce pancreatic
damage manifested by edema, increased serum levels of
pancreatic enzymes, inflammation and necrosis in rats [10],
mice [11] and even healthy human [12]. Although molecular
mechanisms that initiate or apply the form of pancreatitis are
largely unknown, it has been pointed out that premature
activation of pancreatic zymogens within pancreatic tissues
is a key step for progression of the pathological conse-
quence [9]. When P23 is turned out to be unique PSTI-
resistant trypsin, one can speculate that activated P23
trypsin is able to further cleave trypsinogens to trypsins in
the presence of PSTI or other endogenous trypsin inhibitors,
and thus promote the activation cascade. Rat PSTI mRNA
expression has been shown to be upregulated by CCK
[13], it only occurs by one- to two-fold and is much less
responsible than the expression of P23 induced by CCK
analogue. Parallel regulation of anionic trypsinogen and
PSTI was also observed under various dietary conditions
in rats [14]. However, the ratio between the rates of P23 and
PSTI expression might be much higher (P23>>PSTI) in the
setting of caerulein– infusion, resulting in insufficient
amounts of PSTI to attenuate the cascade of trypsin autoac-
tivation promoted by activated P23. In vitro studies shown
in Fig. 5 demonstrate the possibilities that imbalance
between P23 and PSTI cause the promotion of trypsinogen
activation cascade.
In conclusion, rat P23 is found to be a unique PSTI-
resistant trypsin. Taken together with the fact that P23 is
upregulated 14-fold after 24-h caerulein infusion, these
results suggest that rat P23 plays an important role in the
progression of the experimental animal model of caerulein-
induced pancreatitis. An in vitro autoactivation assay system
and recombinant P23 will be useful tools for further inves-
tigation of the mechanism underlying its pathogenesis.
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